HBIO — Stock Film
STOCK FILMSCENE 1/11HBIO · $8.03
Stock Expert AI presents
HBIO
Harvard Bioscience, Inc
~5 min film100% real numbersplain English
WHAT DOES THIS COMPANY DO?
Harvard Bioscience, Inc. What it actually does.

Develops and manufactures cellular and molecular technology instruments. Offers instruments for tissue and organ-based lab research. Now — the numbers.

on the stock market since 2000
328 employees
$36.2M market value
WHERE DOES THE MONEY COME FROM?
90%Instruments, Equipment, Software, and Accessories
Instruments, Equipment, Software, and AccessoriesService, Maintenance, and Warranty Contracts 10%
90% of all revenue comes from a single line: Instruments, Equipment, Software, and Accessories.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

Revenue last year:
$86.6M
The loss that same year:
$56.7M
For every $1 it earns, the company spends $1.7.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

In the vault right now:
$8.6M
DEBT: $44.3M
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

THE PRICE TAG
MARKET VALUE / ANNUAL SALES
0.4×

This company is not turning a profit, so the market is pricing its sales instead: 0.4× for every dollar of annual revenue.

Against companies in its own sector, it looks cheaper than 68% of them.

Analysts' average target sits 25% below today's price.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
70
strong

Clearly above the class average — a step short of the very top.

FINANCIAL STRENGTH
23
very weak

Clearly below the class average.

VALUATION
68
strong

Clearly above the class average — a step short of the very top.

GROWTH
41
weak

Clearly below the class average.

PRICE MOMENTUM
87
very strong

The stock has been running stronger than the market lately.

WORTH WATCHING

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

Growth: Sales growth trails the sector average.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 90% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/1
Executives are buying their own stock

Over the last 12 months, company executives reported 18 buys and 6 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/3
Small sales, big loss

A loss of $56.7M against $86.6M in annual sales. And on top of that, sales fell from the year before.

2
THE RISKS · 2/3
The cash has a countdown

At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.

3
THE RISKS · 3/3
The price sits above analysts’ target

The stock trades 25% above the average analyst price target.

FINALE · THE GRADE
F
26 / 100 · MoonshotScore

On our five-subject report card, HBIO sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: HBIO’s sales are going backwards, and it closed last year at a loss. The road back runs through both.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Sep 12, 2026 · stockexpertai.com · Stock Film